These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 27590836

  • 1. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
    Ethgen O, Sanchez Gonzalez Y, Jeanblanc G, Duguet A, Misurski D, Juday T.
    J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
    [Abstract] [Full Text] [Related]

  • 2. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y.
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
    Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos JC, Dhumeaux D, Yazdanpanah Y.
    Gut; 2012 Feb; 61(2):290-6. PubMed ID: 21930731
    [Abstract] [Full Text] [Related]

  • 5. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
    Younossi Z, Blissett D, Blissett R, Henry L, Younossi Y, Beckerman R, Hunt S.
    Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
    [Abstract] [Full Text] [Related]

  • 6. Hepatitis C in Lebanon: burden of the disease and value of comprehensive screening and treatment.
    Abou Rached A, Abou Kheir S, Saba J, Assaf S, Kassis G, Sanchez Gonzalez Y, Ethgen O.
    J Infect Dev Ctries; 2018 Feb 22; 12(2.1):27S. PubMed ID: 31805002
    [Abstract] [Full Text] [Related]

  • 7. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
    Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A.
    Dig Dis Sci; 2021 Apr 22; 66(4):1315-1326. PubMed ID: 32385703
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y.
    J Viral Hepat; 2016 Oct 22; 23(10):767-79. PubMed ID: 27144512
    [Abstract] [Full Text] [Related]

  • 9. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S.
    Scand J Gastroenterol; 2015 Feb 22; 50(2):233-44. PubMed ID: 25515032
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A, Martel MJ, Tahami Monfared AA, Goeree R.
    J Med Econ; 2016 Feb 22; 19(2):181-92. PubMed ID: 26453248
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ, Khoo AL, Lin L, Teng M, Koh CJ, Lim SG, Lim BP, Dan YY.
    J Gastroenterol Hepatol; 2016 Sep 22; 31(9):1628-37. PubMed ID: 26990023
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.
    J Med Econ; 2014 Jan 22; 17(1):77-87. PubMed ID: 24032626
    [Abstract] [Full Text] [Related]

  • 13. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.
    McEwan P, Kim R, Yuan Y.
    Appl Health Econ Health Policy; 2013 Feb 22; 11(1):53-63. PubMed ID: 23329380
    [Abstract] [Full Text] [Related]

  • 14. Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment.
    Abou Rached A, Abou Kheir S, Saba J, Assaf S, Kassis G, Sanchez Gonzalez Y, Ethgen O.
    Hepat Med; 2018 Feb 22; 10():73-85. PubMed ID: 30214325
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.
    J Med Econ; 2014 Jan 22; 17(1):65-76. PubMed ID: 24160335
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S, Schaetti C, Bruggmann P, Negro F, Razavi H.
    Swiss Med Wkly; 2019 Mar 11; 149():w20026. PubMed ID: 30905063
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA, Chung W, Choi HY, Ki M, Jang ES, Jeong SH.
    Liver Int; 2019 Jan 11; 39(1):60-69. PubMed ID: 29998565
    [Abstract] [Full Text] [Related]

  • 18. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.
    Clin Gastroenterol Hepatol; 2013 Nov 11; 11(11):1503-10. PubMed ID: 23707354
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
    Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA.
    Appl Health Econ Health Policy; 2013 Feb 11; 11(1):65-78. PubMed ID: 23355388
    [Abstract] [Full Text] [Related]

  • 20. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M.
    J Viral Hepat; 2018 Aug 11; 25(8):945-951. PubMed ID: 29478258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.